|
Jul 30
|
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
|
|
Jul 30
|
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint
|
|
Jul 30
|
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
|
|
Jul 29
|
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
|
|
Jul 29
|
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
|
|
Jul 29
|
Exelixis fall over 12% after revenue miss, halts zanzalintinib trial
|
|
Jul 29
|
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges
|
|
Jul 28
|
Exelixis (EXEL) Beats Q2 Earnings Estimates
|
|
Jul 28
|
Exelixis: Q2 Earnings Snapshot
|
|
Jul 28
|
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
|
|
Jul 28
|
Morgan Stanley makes bold S&P 500 projection as U.S. dollar weakens
|
|
Jul 28
|
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
|
|
Jul 28
|
High Growth Tech Stocks In The US To Watch This July 2025
|
|
Jul 28
|
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
|
|
Jul 24
|
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
|
|
Jul 23
|
Exelixis Gains Analyst Confidence as Cancer Studies Advances
|
|
Jul 23
|
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
|
|
Jul 23
|
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
|
|
Jul 22
|
Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
|
|
Jul 21
|
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|